Santhera Pharmaceuticals Holding AG - Company Profile
Powered by 
All the sales intelligence you need on Santhera Pharmaceuticals Holding AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Santhera Pharmaceuticals Holding AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Santhera Pharmaceuticals Holding AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Santhera Pharmaceuticals Holding AG (Santhera) is a specialty pharmaceutical company primarily engaged in the development and commercialization of rare drugs. The company's main focus is on creating treatments for rare neuromuscular and pulmonary diseases with high unmet medical needs, such as Duchenne muscular dystrophy (DMD). Santhera's major product is Agamree (vamorolone), a first-in-class drug candidate designed to offer an alternative to corticosteroids for treating DMD. The company's products are primarily aimed at patients suffering from rare diseases that currently lack effective treatment options. Santhera has licensed vamorolone to Catalyst Pharmaceuticals for North America and to Sperogenix Therapeutics for China. The company's products have been approved by regulatory agencies in the US, European Union, and the UK. Santhera is headquartered in Pratteln, Switzerland.
Headquarters
Switzerland
Address
Hohenrainstrasse 24, Pratteln, Basel-Landschaft, 4133
Website
www.santhera.com
Telephone
41 61 9068950
No of Employees
94
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SANN (SWF)
Revenue (2024)
$92.9M
-62.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-176.6%
(2024 vs 2023)
Market Cap*
$287.4M
Net Profit Margin (2023)
XYZ
-302.6%
(2024 vs 2023)
* As of and is in US$
Santhera Pharmaceuticals Holding AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product: | AGAMREE |
| Agamree (vamorolone): Duchenne Muscular Dystrophy (DMD) |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In January, the company obtained authorization from the Swiss Agency for Therapeutic Products (Swissmedic) for AGAMREE (Vamorolone), intended for the treatment of Duchenne Muscular Dystrophy. |
| 2025 | Contracts/Agreements | In October, the company entered into an agreement with Biomedica for the distribution of AGAMREE (Vamorolone) in Russia. |
| 2025 | Regulatory Approval | In October, the company received approval from Health Canada for AGAMREE (Vamorolone) as a treatment for Duchenne Muscular Dystrophy (DMD). |
Competitor Comparison
| Key Parameters | Santhera Pharmaceuticals Holding AG | Sarepta Therapeutics Inc | NicOx SA | Oncternal Therapeutics Inc | Beacon Therapeutics (USA) Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | France | United States of America | United States of America |
| City | Pratteln | Cambridge | Biot | San Diego | Alachua |
| State/Province | Basel-Landschaft | Massachusetts | Provence - Alpes- Cote d'Azur | California | Florida |
| No. of Employees | 94 | 835 | 11 | 27 | 102 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas Meier | Chairman | Executive Board | 2022 | 63 |
| Dario Eklund | Chief Executive Officer | Senior Management | 2019 | 57 |
| Catherine Isted | Chief Financial Officer | Senior Management | 2025 | - |
| Marc Schrader | Chief Technology Officer | Senior Management | 2024 | - |
| Oliver P. Kronenberg | Chief Legal Officer; Secretary | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer